On May 28, 2020, Atossa Therapeutics announced that it had begun the development of a second COVID-19 program using its proprietary drug candidate AT-301, to be administered by nasal spray.

AT-301 is Atossaﾒs proprietary formula intended for nasal administration in patients immediately following diagnosis of COVID-19 but who had not yet exhibited symptoms severe enough to require hospitalization.